Wnt/β-catenin signaling pathway as novel cancer drug targets

Current Cancer Drug Targets

Volumn 4, Issue 8, 2004, Pages 653-671

  Luu, Hue H ^a   Zhang, Ruiwen ^b   Haydon, Rex C ^a   Rayburn, Elizabeth ^b   Kang, Quan ^a,c   Si, Weike ^a,d   Park, Jong Kyung ^a,e   Wang, Hui ^b   Peng, Ying ^a   Jiang, Wei ^a   He, Tong Chuan ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c CHONGQING MEDICAL UNIVERSITY   (China)

^d THIRD MILITARY MEDICAL UNIVERSITY   (China)

^e The Catholic University of Korea   (South Korea)

Author keywords

catenin; Cancer targets; High throughput screening; Signal transduction; Tumorigenesis; Wnt

Indexed keywords

BETA CATENIN; FRIZZLED PROTEIN; GLYCOPROTEIN; T CELL FACTOR PROTEIN; WNT PROTEIN;

CANCER INHIBITION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG TARGETING; HIGH THROUGHPUT SCREENING; PROTEIN BINDING; REVIEW; SIGNAL TRANSDUCTION; TRANSACTIVATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BETA CATENIN; CYTOSKELETAL PROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASMS; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; WNT PROTEINS;

EID: 19944403876     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009043332709     Document Type: Review

References (293)

1. Kinzler, K. W.; Vogelstein, B. Lessons from hereditary colorectal cancer. Cell 1996, 87, 159-170.
2. Polakis, P. The oncogenic activation of beta-catenin. Curr. Opin. Genet. Dev. 1999, 9, 15-21.
3. Waltzer, L.; Bienz, M. The control of beta-catenin and TCF during embryonic development and cancer. Cancer Metastasis Rev. 1999, 18, 231-246.
4. Behrens, J. Control of beta-catenin signaling in tumor development. Ann. NY Acad. Sci. 2000, 910, 21-33; discussion 33-25.
5. Sharma, R. P.; Chopra, V. L. Effect of the Wingless (wgl) mutation on wing and haltere development in Drosophila melanogaster. Dev. Biol. 1976, 48, 461-465.
6. Nusse, R.; Varmus, H. E. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 1982, 31, 99-109.
7. Rijsewijk, F.; Schuermann, M.; Wagenaar, E.; Parren, P.; Weigel, D.; Nusse, R. The Drosophila homolog of the mouse mammary oncogene int-1 is identical to the segment polarity gene wingless. Cell 1987, 50, 649-657.
8. Wodarz, A.; Nusse, R. Mechanisms of Wnt signaling in development. Annu. Rev. Cell Dev. Biol. 1998, 14, 59-88.
9. Willert, K.; Nusse, R. Beta-catenin: a key mediator of Wnt signaling. Curr. Opin. Genet. Dev. 1998, 8, 95-102.
10. Yang-Snyder, J.; Miller, J. R.; Brown, J. D.; Lai, C. J.; Moon, R. T. A frizzled homolog functions in a vertebrate Wnt signaling pathway. Curr. Biol. 1996, 6, 1302-1306.
11. He, X.; Saint-Jeannet, J. P.; Wang, Y.; Nathans, J.; Dawid, I.; Varmus, H. A member of the Frizzled protein family mediating axis induction by Wnt- 5A. Science 1997, 275, 1652-1654.
12. Bhanot, P.; Brink, M.; Samos, C. H.; Hsieh, J. C.; Wang, Y.; Macke, J. P.; Andrew, D.; Nathans, J.; Nusse, R. A new member of the frizzled family from Drosophila functions as a Wingless receptor. Nature 1996, 382, 225-230.
13. Pinson, K. I.; Brennan, J.; Monkley, S.; Avery, B. J.; Skarnes, W. C. An LDL-receptor-related protein mediates Wnt signalling in mice. Nature 2000, 407, 535-538.
14. Tamai, K.; Semenov, M.; Kato, Y.; Spokony, R.; Liu, C.; Katsuyama, Y.; Hess, F.; Saint-Jeannet, J. P.; He, X. LDL-receptor-related proteins in Wnt signal transduction. Nature 2000, 407, 530-535.
15. Noordermeer, J.; Klingensmith, J.; Perrimon, N.; Nusse, R. dishevelled and armadillo act in the wingless signalling pathway in Drosophila. Nature 1994, 367, 80-83.
16. Zeng, L.; Fagotto, F.; Zhang, T.; Hsu, W.; Vasicek, T. J.; Perry, W. L. 3rd; Lee, J. J.; Tilghman, S. M.; Gumbiner, B. M.; Costantini, F. The mouse Fused locus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates embryonic axis formation. Cell 1997, 90, 181-192.
17. Behrens, J.; Jerchovv, B. A.; Wurtele, M.; Grimm, J.; Asbrand, C.; Wirtz, R.; Kuhl, M.; Wedlich, D.; Birchmeier, W. Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science 1998, 280, 596-599.
18. Hart, M. J.; de los Santos, R.; Albert, I. N.; Rubinfeld, B.; Polakis, P. Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. Curr. Biol. 1998, 8, 573-581.
19. Ikeda, S.; Kishida, S.; Yamamoto, H.; Murai, H.; Koyama, S.; Kikuchi, A. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta- dependent phosphorylation of beta-catenin. EMBO J. 1998, 17, 1371-1384.
20. Nakamura, T.; Flamada, F.; Ishidate, T.; Anai, K.; Kawahara, K.; Toyoshima, K.; Akiyama, T. Axin, an inhibitor of the Wnt signalling pathway, interacts with beta-catenin, GSK-3beta and APC and reduces the beta-catenin level. Genes Cells 1998, 3, 395-403.
21. Sakanaka, C.; Weiss, J. B.; Williams, L. T. Bridging of beta-catenin and glycogen synthase kinase-3beta by axin and inhibition of beta-catenin-mediated transcription. Proc. Natl. Acad. Sci. USA 1998, 95, 3020-3023.
22. Groden, J.; Thliveris, A.; Samowitz, W.; Carlson, M.; Gelbert, L.; Albertsen, H.; Joslyn, G.; Stevens, J.; Spirio, L.; Robertson, M.; Sargeant, L.; Krapcho, K.; Wolff, E; Randall, B.; Hughes, J. P.; Warrington, J.; Mcpherson, J.; Wasmuth, J.; Paslier, D. L.; Abderrahim, H.; Cohen, D.; Leppert, M.; White, R. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991, 60, 589-600.
23. Kinzler, K. W.; Nilbert, M. C.; Su, L. K.; Vogelstein, B.; Bryan, T. M.; Levy, D. B.; Smith, K. J.; Preisinger, A. C.; Hedge, P.; McKechnie, D.; Finniear, R.; Markham, A.; Groffen, J.; Boguski, M. S.; Altschul, S. F.; Horii, A.; Ando, H.; Miyoshi, Y.; Miki, Y.; Nishisho, I.; Nakamura, Y. Identification of FAP locus genes from chromosome 5q21. Science 1991, 253, 661-665.
24. He, X.; Saint-Jeannet, J. P.; Woodgett, J. R.; Varmus, H. E.; Dawid, I. B. Glycogen synthase kinase-3 and dorsoventral patterning in Xenopus embryos. Nature 1995, 374, 617-622. [Published erratum appears in Nature 1995, 375, 253].
25. He, X.; Saint-Jeannet, J. P.; Woodgett, J. R.; Varmus, H. E.; Dawid, I. B. Glycogen synthase kinase-3 and dorsoventral patterning in Xenopus embryos. Nature 1995, 374, 617-622. [Published erratum appears in Nature 1995, 375, 253].
26. Dominguez, I.; Itoh, K.; Sokol, S. Y. Role of glycogen synthase kinase 3 beta as a negative regulator of dorsoventral axis formation in Xenopus embryos. Proc. Natl. Acad. Sci. USA 1995, 92, 8498-8502.
27. Seidensticker, M. J.; Behrens, J. Biochemical interactions in the wnt pathway. Biochim. Biophys. Acta 2000, 1495, 168-182.
28. Cadigan, K. M.; Nusse, R. Wnt signaling: a common theme in animal development. Genes Dev. 1997, 11, 3286-3305.
29. Salic, A.; Lee, E.; Mayer, L.; Kirschner, M. W. Control of beta-catenin stability: reconstitution of the cytoplasmic steps of the wnt pathway in Xenopus egg extracts. Mol. Cell 2000, 5, 523-532.
30. Spiegelman, V. S.; Slaga, T. J.; Pagano, M.; Minamoto, T.; Ronai, Z.; Fuchs, S. Y. Wnt/beta-catenin signaling induces the expression and activity of betaTrCP ubiquitin ligase receptor. Mol. Cell 2000, 5, 877-882.
31. Liu, C.; Kato, Y.; Zhang, Z.; Do, V. M.; Yankner, B. A.; He, X. Beta-Trcp couples beta-catenin phosphorylation-degradation and regulates Xenopus axis formation. Proc. Natl. Acad. Sci. USA 1999, 96, 6273-6278.
32. Molenaar, M.; van de Wetering, M.; Oosterwegel, M.; Peterson-Maduro, J.; Godsave, S.; Korinek, V.; Roose, J.; Destree, O.; Clevers, H. XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos. Cell 1996, 86, 391-399.
33. Behrens, J.; von Kries, J. P.; Kuhl, M.; Bruhn, L.; Wedlich, D.; Grosschedl, R.; Birchmeier, W. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 1996, 382, 638-642.
34. Polakis, P. Wnt signaling and cancer. Genes Dev. 2000, 14, 1837-1851.
35. He, T. C.; Sparks, A. B.; Rago, C.; Hermeking, H.; Zawel, L.; da Costa, L. T.; Morin, P. J.; Vogelstein, B.; Kinzler, K. W. Identification of c-MYC as a target of the APC pathway [see comments]. Science 1998, 281, 1509-1512.
36. He, T. C.; Chan, T. A.; Vogelstein, B.; Kinzler, K. W. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999, 99, 335-345.
37. Tetsu, O.; McCormick, F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999, 398, 422-426.
38. Shtutman, M.; Zhurinsky, J.; Simcha, I.; Albanese, C.; D'Amico, M.; Pestell, R.; Ben-Ze'ev, A. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc. Natl. Acad. Sci. USA 1999, 96, 5522-5527.
39. Mann, B.; Gelos, M.; Siedow, A.; Hanski, M. L.; Gratchev, A.; Ilyas, M.; Bodmer, W. F.; Moyer, M. P.; Riecken, E. O.; Buhr, H. J.; Hanski, C. Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc. Natl. Acad. Sci. USA 1999, 96, 1603-1608.
40. Brabletz, T.; Jung, A.; Dag, S.; Hlubek, F.; Kirchner, T. Beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am. J. Pathol. 1999, 155, 1033-1038.
41. Crawford, H. C.; Fingleton, B. M.; Rudolph-Owen, L. A.; Goss, K. J.; Rubinfeld, B.; Polakis, P.; Matrisian, L. M. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene 1999, 18, 2883-2891.
42. Pennica, D.; Swanson, T. A.; Welsh, J. W.; Roy, M. A.; Lawrence, D. A.; Lee, J.; Brush, J.; Taneyhill, L. A.; Deuel, B.; Lew, M.; Watanabe, C.; Cohen, R. L.; Melhem, M. F.; Finley, G. G.; Quirke, P.; Goddard, A. D.; Hillan, K. J.; Gurney, A. L.; Botstein, D.; Levine, A. J. WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc. Natl. Acad. Sci. USA 1998, 95, 14717-14722.
43. Xu, L.; Corcoran, R. B.; Welsh, J. W.; Pennica, D.; Levine, A. J. WISP-1 is a wnt-1- and beta-catenin-responsive oncogene [In Process Citation]. Genes Dev. 2000, 14, 585-595.
44. Levanon, D.; Goldstein, R. E.; Bernstein, Y.; Tang, H.; Goldenberg, D.; Stifani, S.; Paroush, Z.; Groner, Y. Transcriptional repression by AML1 and LEF-1 is mediated by the TLE/Groucho corepressors. Proc. Natl. Acad. Sci. USA 1998, 95, 11590-11595.
45. Roose, J.; Molenaar, M.; Peterson, J.; Hurenkamp, J.; Brantjes, H.; Moerer, P.; van de Wetering, M.; Destree, O.; Clevers, H. The Xenopus Wnt effector XTcf-3 interacts with Groucho-related transcriptional repressors. Nature 1998, 395, 608-612.
46. Cavallo, R. A.; Cox, R. T.; Moline, M. M.; Roose, J.; Polevoy, G. A.; Clevers, H.; Peifer, M.; Bejsovec, A. Drosophila Tcf and Groucho interact to repress Wingless signalling activity. Nature 1998, 395, 604-608.
47. Tago, K.; Nakamura, T.; Nishita, M.; Hyodo, J.; Nagai, S.; Murata, Y.; Adachi, S.; Ohwada, S.; Morishita, Y.; Shibuya, H.; Akiyama, T. Inhibition of Wnt signaling by ICAT, a novel beta-catenin-interacting protein. Genes Dev. 2000, 14, 1741-1749.
48. Hino, S.; Kishida, S.; Michiue, T.; Fukui, A.; Sakamoto, I.; Takada, S.; Asashima, M.; Kikuchi, A. Inhibition of the wnt signaling pathway by idax, a novel dvl-binding protein. Mol. Cell. Biol. 2001, 21, 330-342.
49. Sakamoto, I.; Kishida, S.; Fukui, A.; Kishida, M.; Yamamoto, H.; Hino, S.; Michiue, T.; Takada, S.; Asashima, M.; Kikuchi, A. A novel beta -catenin-binding protein inhibits beta -catenin-dependent tcf activation and axis formation. J. Biol. Chem. 2000, 275, 32871-32878.
50. Kadoya, T.; Kishida, S.; Fukui, A.; Hinoi, T.; Michiue, T.; Asashima, M.; Kikuchi, A. Inhibition of wnt signaling pathway by a novel axin-binding protein. J. Biol. Chem. 2000, 275, 37030-37037.
51. Soriano, S.; Kang, D. E.; Fu, M.; Pestell, R.; Chevallier, N.; Zheng, H.; Koo, E. H. Presenilin 1 negatively regulates beta-catenin/T cell factor/lymphoid enhancer factor-1 signaling independently of beta-amyloid precursor protein and notch processing. J. Cell Biol. 2001, 152, 785-794.
52. Noll, E.; Medina, M.; Hartley, D.; Zhou, J.; Perrimon, N.; Kosik, K. S. Presenilin affects arm/beta-catenin localization and function in Drosophila. Dev. Biol. 2000, 227, 450-464.
53. Barker, N.; Hurlstone, A.; Musisi, H.; Miles, A.; Bienz, M.; Clevers, H. The chromatin remodelling factor Brg-1 interacts with beta-catenin to promote target gene activation. EMBO J. 2001, 20, 4935-4943.
54. Sampson, E. M.; Haque, Z. K.; Ku, M. C.; Tevosian, S. G.; Albanese, C.; Pestell, R. G.; Paulson, K. E.; Yee, A. S. Negative regulation of the Wnt-beta-catenin pathway by the transcriptional repressor HBP1. EMBO J. 2001, 20, 4500-4511.
55. Meng, X.; Poon, R.; Zhang, X.; Cheah, A.; Ding, Q.; Hui Cc, C.; Alman, B. Suppressor of fused negatively regulates beta-catenin signaling. J. Biol. Chem. 2001, 26, 26.
56. Wang, S. S.; Esplin, E. D.; Li, J. L.; Huang, L.; Gazdar, A.; Minna, J.; Evans, G. A. Alterations of the PPP2R1B gene in human lung and colon cancer. Science 1998, 282, 284-287.
57. Seeling, J. M.; Miller, J. R.; Gil, R.; Moon, R. T.; White, R.; Virshup, D. M. Regulation of beta-catenin signaling by the B56 subunit of protein phosphatase 2A. Science 1999, 283, 2089-2091.
58. Ikeda, S.; Kishida, M.; Matsuura, Y.; Usui, H.; Kikuchi, A. GSK-3beta-dependent phosphorylation of adenomatous polyposis coli gene product can be modulated by beta-catenin and protein phosphatase 2A complexed with Axin. Oncogene 2000, 19, 537-545.
59. Peters, J. M.; McKay, R. M.; McKay, J. P.; Graff, J. M. Casein kinase 1 transduces Wnt signals. Nature 1999, 401, 345-350.
60. Sakanaka, C.; Leong, P.; Xu, L.; Harrison, S. D.; Williams, L. T. Casein kinase iepsilon in the wnt pathway: regulation of beta-catenin function. Proc. Natl. Acad. Sci. USA 1999, 96, 12548-12552.
61. Lickert, H.; Bauer, A.; Kemler, R.; Stappert, J. Casein kinase 11 phosphorylation of E-cadherin increases E- cadherin/beta-catenin interaction and strengthens cell-cell adhesion. J. Biol. Chem. 2000, 275, 5090-5095.
62. Song, D. H.; Sussman, D. J.; Seldin, D. C. Endogenous protein kinase CK2 participates in Wnt signaling in mammary epithelial cells. J. Biol. Chem. 2000, 275, 23790-23797.
63. Liu, C.; Li, Y.; Semenov, M.; Han, C.; Baeg, G. H.; Tan, Y.; Zhang, Z.; Lin, X.; He, X. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002, 108, 837-847.
64. Liu, J.; Stevens, J.; Rote, C. A.; Yost, H. J.; Hu, Y.; Neufeld, K. L.; White, R. L.; Matsunami, N. Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol. Cell 2001, 7, 927-936.
65. Matsuzawa, S. I.; Reed, J. C. Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses. Mol. Cell 2001, 7, 915-926.
66. Eastman, Q.; Grosschedl, R. Regulation of LEF-1/TCF transcription factors by Wnt and other signals. Curr. Opin. Cell Biol. 1999, 11, 233-240.
67. Kawasaki, Y.; Senda, T.; Ishidate, T.; Koyama, R.; Morishita, T.; Iwayama, Y.; Higuchi, O.; Akiyama, T. Asef, a link between the tumor suppressor APC and G-protein signaling. Science 2000, 289, 1194-1197.
68. Novak, A.; Hsu, S. C.; Leung-Hagesteijn, C.; Radeva, G.; Papkoff, J.; Montesano, R.; Roskelley, C.; Grosschedl, R.; Dedhar, S. Cell adhesion and the integrin-linked kinase regulate the LEF-1 and beta-catenin signaling pathways. Proc. Natl. Acad. Sci. USA 1998, 95, 4374-4379.
69. Papkoff, J.; Aikawa, M. WNT-1 and HGF regulate GSK3 beta activity and beta-catenin signaling in mammary epithelial cells. Biochem. Biophys. Res. Commun. 1998, 247, 851-858.
70. Hiscox, S.; Jiang, W. G. Hepatocyte growth factor/scatter factor disrupts epithelial tumour cell- cell adhesion: involvement of beta-catenin. Anticancer Res. 1999, 19, 509-517.
71. Goruppi, S.; Chiaruttini, C.; Ruaro, M. E.; Varnum, B.; Schneider, C. Gas6 Induces Growth, beta-Catenin Stabilization, and T-Cell Factor Transcriptional Activation in Contact-Inhibited C57 Mammary Cells. Mol. Cell Biol. 2001, 21, 902-915.
72. Playford, M. P.; Bicknell, D.; Bodmer, W. F.; Macaulay, V. M. Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of beta -catenin [In Process Citation]. Proc. Natl. Acad. Sci. USA 2000, 97, 12103-12108.
73. Desbois-Mouthon, C.; Cadoret, A.; Blivet-Van Eggelpoel, M. J.; Bertrand, F.; Cherqui, G.; Perret, C.; Capeau, J. Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. Oncogene 2001, 20, 252-259.
74. Morali, O. G.; Delmas, V.; Moore, R.; Jeanney, C.; Thiery, J. P.; Larue, L. IGF-II induces rapid beta-catenin relocation to the nucleus during epithelium to mesenchyme transition. Oncogene 2001, 20, 4942-4950.
75. Hashimoto, M.; Sagara, Y.; Langford, D.; Everall, I. P.; Mallory, M.; Everson, A.; Digicaylioglu, M.; Masliah, E. Fibroblast growth factor 1 regulates signaling via the glycogen synthase kinase-3beta pathway. Implications for neuroprotection. J. Biol. Chem. 2002, 277, 32985-32991.
76. Carmeliet, P.; Lampugnani, M. G.; Moons, L.; Breviario, F.; Compernolle, V.; Bono, F.; Balconi, G.; Spagnuolo, R.; Oostuyse, B.; Dewerchin, M.; Zanetti, A.; Angellilo, A.; Mattot, V.; Nuyens, D.; Lutgens, E.; Clotman, F.; de Ruiter, M. C.; Gittenberger-de Groot, A.; Poelmann, R.; Lupu, F.; Herbert, J. M.; Collen, D.; Dejana, E. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 1999, 98, 147-157.
77. Ishitani, T.; Ninomiya-Tsuji, J.; Nagai, S.; Nishita, M.; Meneghini, M.; Barker, N.; Waterman, M.; Bowerman, B.; Clevers, H.; Shibuya, H.; Matsumoto, K. The TAK1-NLK-MAPK-related pathway antagonizes signalling between beta- catenin and transcription factor TCF. Nature 1999, 399, 798-802.
78. Li, L.; Yuan, H.; Xie, W.; Mao, J.; Caruso, A. M.; McMahon, A.; Sussman, D. J.; Wu, D. Dishevelled proteins lead to two signaling pathways. Regulation of LEF- 1 and c-Jun N-terminal kinase in mammalian cells. J. Biol. Chem. 1999, 274, 129-134.
79. Zhang, Y.; Neo, S. Y.; Wang, X.; Han, J.; Lin, S. C. Axin forms a complex with MEKK1 and activates c-Jun NH(2)-terminal kinase/stress-activated protein kinase through domains distinct from Wnt signaling. J. Biol. Chem. 1999, 274, 35247-35254.
80. Kuhl, M.; Sheldahl, L. C.; Park, M.; Miller, J. R.; Moon, R. T. The Wnt/Ca2+ pathway: a new vertebrate Wnt signaling pathway takes shape. Trends Genet. 2000, 16, 279-283.
81. Kuhl, M.; Sheldahl, L. C.; Malbon, C. C.; Moon, R. T. Ca(2+)/calmodulin-dependent protein kinase II is stimulated by Wnt and Frizzled homologs and promotes ventral cell fates in Xenopus. J. Biol. Chem. 2000, 275, 12701-12711.
82. Nishita, M.; Hashimoto, M. K.; Ogata, S.; Laurent, M. N.; Ueno, N.; Shibuya, H.; Cho, K. W. Interaction between Wnt and TGF-beta signalling pathways during formation of Spemann's organizer. Nature 2000, 403, 781-785.
83. Sheldahl, L. C.; Park, M.; Malbon, C. C.; Moon, R. T. Protein kinase C is differentially stimulated by Wnt and Frizzled homologs in a G-protein-dependent manner. Curr. Biol. 1999, 9, 695-698.
84. Chen, R. H.; Ding, W. V.; McCormick, F. Wnt signaling to beta-catenin involves two interactive components. Glycogen synthase kinase-3beta inhibition and activation of protein kinase C. J. Biol. Chem. 2000, 275, 17894-17899.
85. Murray, N. R.; Davidson, L. A.; Chapkin, R. S.; Clay Gustafson, W.; Schattenberg, D. G.; Fields, A. P. Overexpression of protein kinase C betaII induces colonic hyperproliferation and increased sensitivity to colon carcinogenesis. J. Cell Biol. 1999, 145, 699-711.
86. Easwaran, V.; Pishvaian, M.; Salimuddin; B. S. Cross-regulation of beta-catenin-LEF/TCF and retinoid signaling pathways. Curr. Biol. 1999, 9, 1415-1418.
87. Tada, M.; Concha, M. L.; Heisenberg, C. P. Non-canonical Wnt signalling and regulation of gastrulation movements. Semin. Cell Dev. Biol. 2002, 13, 251-260.
88. Rubinfeld, B.; Souza, B.; Albert, I.; Muller, O.; Chamberlain, S. H.; Masiarz, F. R.; Munemitsu, S.; Polakis, P. Association of the APC gene product with beta-catenin. Science 1993, 262, 1731-1734.
89. Su, L. K.; Vogelstein, B.; Kinzler, K. W. Association of the APC tumor suppressor protein with catenins. Science 1993, 262, 1734-1737.
90. Morin, P. J.; Sparks, A. B.; Korinek, V.; Barker, N.; Clevers, H.; Vogelstein, B.; Kinzler, K. W. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997, 275, 1787-1790.
91. Sparks, A. B.; Morin, P. J.; Vogelstein, B.; Kinzler, K. W. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res. 1998, 58, 1130-1134.
92. Rubinfeld, B.; Robbins, P.; El-Gamil, M.; Albert, I.; Porfiri, E.; Polakis, P. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 1997, 275, 1790-1792.
93. Voeller, H. J.; Truica, C. I.; Gelmann, E. P. Beta-catenin mutations in human prostate cancer. Cancer Res. 1998, 58, 2520-2523.
94. de La Coste, A.; Romagnolo, B.; Billuart, P.; Renard, C. A.; Buendia, M. A.; Soubrane, O.; Fabre, M.; Chelly, J.; Beldjord, C.; Kahn, A.; Perret, C. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc. Natl. Acad. Sci. USA 1998, 95, 8847-8851.
95. Fukuchi, T.; Sakamoto, M.; Tsuda, H.; Maruyama, K.; Nozawa, S.; Hirohashi, S. Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res. 1998, 58, 3526-3528.
96. Koch, A.; Denkhaus, D.; Albrecht, S.; Leuschner, I.; von Schweinitz, D.; Pietsch, T. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Cancer Res. 1999, 59, 269-273.
97. Kobayashi, K.; Sagae, S.; Nishioka, Y.; Tokino, T.; Kudo, R. Mutations of the beta-catenin gene in endometrial carcinomas. Jpn. J. Cancer Res. 1999, 90, 55-59.
98. Iwao, K.; Miyoshi, Y.; Nawa, G.; Yoshikawa, H.; Ochi, T.; Nakamura, Y. Frequent beta-catenin abnormalities in bone and soft-tissue tumors. Jpn. J. Cancer Res. 1999, 90, 205-209.
99. Chan, E. F.; Gat, U.; McNiff, J. M.; Fuchs, E. A common human skin tumour is caused by activating mutations in beta- catenin. Nat. Genet. 1999, 21, 410-413.
100. Garcia-Rostan, G.; Tallini, G.; Herrero, A.; D'Aquila, T. G.; Carcangiu, M. L.; Rimm, D. L. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res. 1999, 59, 1811-1815.
101. Ogawa, K.; Yamada, Y.; Kishibe, K.; Ishizaki, K.; Tokusashi, Y. Beta-catenin mutations are frequent in hepatocellular carcinomas but absent in adenomas induced by diethylnitrosamine in B6C3F1 mice. Cancer Res. 1999, 59, 1830-1833.
102. Sagae, S.; Kobayashi, K.; Nishioka, Y.; Sugimura, M.; Ishioka, S.; Nagata, M.; Terasawa, K.; Tokino, T.; Kudo, R. Mutational analysis of beta-catenin gene in Japanese ovarian carcinomas: frequent mutations in endometrioid carcinomas. Jpn. J. Cancer Res. 1999, 90, 510-515.
103. Blaker, H.; Hofmann, W. J.; Rieker, R. J.; Penzel, R.; Graf, M.; Otto, H. F. Beta-catenin accumulation and mutation of the CTNNB1 gene in hepatoblastoma. Genes Chromosomes Cancer 1999, 25, 399-402.
104. Wright, K.; Wilson, P.; Morland, S.; Campbell, I.; Walsh, M.; Hurst, T.; Ward, B.; Cummings, M.; Chenevix-Trench, G. Beta-catenin mutation and expression analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16% of endometrioid tumours. Int. J. Cancer 1999, 82, 625-629.
105. Gamallo, C.; Palacios, J.; Moreno, G.; Calvo de Mora, J.; Suarez, A.; Armas, A. Beta-catenin expression pattern in stage 1 and 11 ovarian carcinomas: relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. Am. J. Pathol. 1999, 155, 527-536.
106. Legoix, P.; Bluteau, O.; Bayer, J.; Perret, C.; Balabaud, C.; Belghiti, J.; Franco, D.; Thomas, G.; Laurent-Puig, P.; Zucman-Rossi, J. Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. Oncogene 1999, 18, 4044-4046.
107. Koesters, R.; Ridder, R.; Kopp-Schneider, A.; Betts, D.; Adams, V.; Niggli, F.; Briner, J.; von Knebel Doeberitz, M. Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors. Cancer Res. 1999, 59, 3880-3882.
108. Park, W. S.; Oh, R. R.; Park, J. Y.; Lee, S. H.; Shin, M. S.; Kim, Y. S.; Kim, S. Y.; Lee, H. K.; Kim, P. J.; Oh, S. T.; Yoo, N. J.; Lee, J. Y. Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer. Cancer Res. 1999, 59, 4257-4260.
109. Nhieu, J. T.; Renard, C. A.; Wei, Y.; Cherqui, D.; Zafrani, E. S.; Buendia, M. A. Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am. J. Pathol. 1999, 155, 703-710.
110. Huang, H.; Fujii, H.; Sankila, A.; Mahler-Araujo, B. M.; Matsuda, M.; Cathomas, G.; Ohgaki, H. Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection. Am. J. Pathol. 1999, 155, 1795-1801.
111. Terris, B.; Pineau, P.; Bregeaud, L.; Valla, D.; Belghiti, J.; Tiollais, P.; Degott, C.; Dejean, A. Close correlation between beta-catenin gene alterations and nuclear accumulation of the protein in human hepatocellular carcinomas. Oncogens 1999, 18, 6583-6588.
112. Kondo, Y.; Kanai, Y.; Sakamoto, M.; Genda, T.; Mizokami, M.; Ueda, R.; Hirohashi, S. Beta-catenin accumulation and mutation of exon 3 of the beta-catenin gene in hepatocellular carcinoma Jpn. J. Cancer Res. 1999, 90, 1301-1309.[Published erratum appears in Jpn. J. Cancer Res. 2000 91, 270].
113. Kondo, Y.; Kanai, Y.; Sakamoto, M.; Genda, T.; Mizokami, M.; Ueda, R.; Hirohashi, S. Beta-catenin accumulation and mutation of exon 3 of the beta-catenin gene in hepatocellular carcinoma Jpn. J. Cancer Res. 1999, 90, 1301-1309.[Published erratum appears in Jpn. J. Cancer Res. 2000 91, 270].
114. Ikeda, T.; Yoshinaga, K.; Semba, S.; Kondo, E.; Ohmori, H.; Horii, A. Mutational analysis of the CTNNB1 (beta-catenin) gene in human endometrial cancer: frequent mutations at codon 34 that cause nuclear accumulation. Oncol. Rep. 2000, 7, 323-326.
115. Wei, Y.; Fabre, M.; Branchereau, S.; Gauthier, F.; Perilongo, G.; Buendia, M. A. Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas. Oncogene 2000, 19, 498-504.
116. Jeng, Y. M.; Wu, M. Z.; Mao, T. L.; Chang, M. H.; Hsu, H. C. Somatic mutations of beta-catenin play a crucial role in the tumorigenesis of sporadic hepatoblastoma. Cancer Lett. 2000, 152, 45-51.
117. Eberhart, C. G.; Tihan, T.; Burger, P. C. Nuclear localization and mutation of beta-catenin in medulloblastomas. J. Neuropathol. Exp. Neurol 2000, 59, 333-337.
118. Hsu, H. C.; Jeng, Y. M.; Mao, T. L.; Chu, J. S.; Lai, P. L.; Peng, S. Y. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am. J. Pathol. 2000, 157, 763-770.
119. Kim, Y. S.; Kang, Y. K.; Kim, J. B.; Han, S. A.; Kim, K. I.; Paik, S. R. Beta-catenin expression and mutational analysis in renal cell carcinomas. Pathol. Int. 2000, 50, 725-730.
120. Choi, Y. W.; Heath, E. I.; Heitmiller, R.; Forastiere, A. A.; Wu, T. T. Mutations in beta-catenin and APC genes are uncommon in esophageal and esophagogastric junction adenocarcinomas. Mod. Pathol. 2000, 13, 1055-1059.
121. Schlosshauer, P. W.; Pirog, E. C.; Levine, R. L.; Ellenson, L. H. Mutational analysis of the CTNNBI and APC genes in uterine endometrioid carcinoma. Mod. Pathol. 2000, 13, 1066-1071.
122. Saito, T.; Oda, Y.; Sakamoto, A.; Tamiya, S.; Kinukawa, N.; Hayashi, K.; Iwamoto, Y.; Tsuneyoshi, M. Prognostic value of the preserved expression of the E-cadherin and catenin families of adhesion molecules and of beta-catenin mutations in synovial sarcoma. J. Pathol. 2000, 192, 342-350.
123. Chesire, D. R.; Ewing, C. M.; Sauvageot, J.; Bova, G. S.; Isaacs, W. B. Detection and analysis of beta-catenin mutations in prostate cancer. Prostate 2000, 45, 323-334.
124. Maiti, S.; Alam, R.; Amos, C. I.; Huff, V. Frequent association of beta-catenin and WT1 mutations in Wilms tumors. Cancer Res. 2000, 60, 6288-6292.
125. Zhu, X.; Kanai, Y.; Saito, A.; Kondo, Y.; Hirohashi, S. Aberrant expression of beta-catenin and mutation of exon 3 of the beta-catenin gene in renal and urothelial carcinomas. Pathol. Int. 2000, 50, 945-952.
126. Zurawel, R. H.; Chiappa, S. A.; Allen, C.; Raffel, C. Sporadic medulloblastomas contain oncogenic beta-catenin mutations. Cancer Res. 1998, 58, 896-899.
127. Suarez, H. G. Activated oncogenes in human tumors. Anticancer Res. 1989, 9, 1331-1343.
128. Prins, J.; De Vries, E. G.; Mulder, N. H. The myc family of oncogenes and their presence and importance in small- cell lung carcinoma and other tumour types. Anticancer Res. 1993, 13, 1373-1385.
129. Donnellan, R.; Chetty, R. Cyclin D1 and human neoplasia. Mol. Pathol. 1998, 51, 1-7.
130. Morin, P. J. Beta-catenin signaling and cancer. Bioessays 1999, 21, 1021-1030.
131. Rimm, D. L.; Caca, K.; Hu, G.; Harrison, F. B.; Fearon, E. R. Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am. J. Pathol. 1999, 154, 325-329.
132. Toyoyama, H.; Nuruki, K.; Ogawa, H.; Yanagi, M.; Matsumoto, H.; Nishijima, H.; Shimotakahara, T.; Aikou, T.; Ozawa, M. The reduced expression of e-cadherin, alpha-catenin and gamma-catenin but not beta-catenin in human lung cancer. Oncol. Rep. 1999, 6, 81-85.
133. Kimura, Y.; Shiozaki, H.; Doki, Y.; Yamamoto, M.; Utsunomiya, T.; Kawanishi, K.; Fukuchi, N.; Inoue, M.; Tsujinaka, T.; Monden, M. Cytoplasmic beta-catenin in esophageal cancers. Int. J. Cancer 1999, 84, 174-178.
134. Nei, H.; Saito, T.; Yamasaki, H.; Mizumoto, H.; Ito, E.; Kudo, R. Nuclear localization of beta-catenin in normal and carcinogenic endometrium. Mol. Carcinog. 1999, 25, 207-218.
135. Lo Muzio, L.; Staibano, S.; Pannone, G.; Grieco, M.; Mignogna, M. D.; Cerrato, A.; Testa, N. F.; De Rosa, G. Beta- and gamma-catenin expression in oral squamous cell carcinomas. Anticancer Res. 1999, 19, 3817-3826.
136. Bilim, V.; Kawasaki, T.; Katagiri, A.; Wakatsuki, S.; Takahashi, K.; Tomita, Y. Altered expression of beta-catenin in renal cell cancer and transitional cell cancer with the absence of beta-catenin gene mutations. Clin. Cancer Res. 2000, 6, 460-466.
137. Kuhnen, C.; Herter, P.; Muller, O.; Muehlberger, T.; Krause, L.; Homann, H.; Steinau, H. U.; Muller, K. M. Beta-catenin in soft tissue sarcomas: expression is related to proliferative activity in high-grade sarcomas. Mod. Pathol. 2000, 13, 1005-1013.
138. Bian, Y. S.; Osterheld, M. C.; Bosman, F. T.; Fontolliet, C.; Benhattar, J. Nuclear accumulation of beta-catenin is a common and early event during neoplastic progression of Barrett esophagus. Am. J. Clin. Pathol. 2000, 114, 583-590.
139. Saito, T.; Katagiri, A.; Watanabe, R.; Tanikawa, T.; Kawasaki, T.; Tomita, Y.; Takahashi, K. Expression of E-cadherin and catenins on testis tumor. Urol. Int. 2000, 65, 140-143.
140. Yano, H.; Hara, A.; Takenaka, K.; Nakatani, K.; Shinoda, J.; Shimokawa, K.; Yoshimi, N.; Mori, H.; Sakai, N. Differential expression of beta-catenin in human glioblastoma multiforme and normal brain tissue. Neurol. Res. 2000, 22, 650-656.
141. Ougolkov, A.; Mai, M.; Takahashi, Y.; Omote, K.; Bilim, V.; Shimizu, A.; Minamoto, T. Altered expression of beta-catenin and c-erbB-2 in early gastric cancer. J. Exp. Clin. Cancer Res. 2000, 19, 349-355.
142. Miyazawa, K.; Iwaya, K.; Kuroda, M.; Harada, M.; Serizawa, H.; Koyanagi, Y.; Sato, Y.; Mizokami, Y.; Matsuoka, T.; Mukai, K. Nuclear accumulation of beta-catenin in intestinal-type gastric carcinoma: correlation with early tumor invasion. [In Process Citation]. Virchows Arch. 2000, 437, 508-513.
143. Semba, S.; Han, S. Y.; Ikeda, H.; Horii, A. Frequent nuclear accumulation of beta-catenin in pituitary adenoma. Cancer 2001, 91, 42-48.
144. Haydon, R. C.; Deyrup, A.; Ishikawa, A.; Heck, R.; Jiang, W.; Zhou, L.; Feng, T.; King, D.; Cheng, H.; Breyer, B.; Peabody, T.; Simon, M. A.; Montag, A. G.; He, T. C. Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma. Int. J. Cancer 2002, 102, 338-342.
145. Miller, J. R.; Hocking, A. M.; Brown, J. D.; Moon, R. T. Mechanism and function of signal transduction by the Wnt/beta-catenin and Wnt/Ca2+ pathways. Oncogene 1999, 18, 7860-7872.
146. Gat, U.; DasGupta, R.; Degenstein, L.; Fuchs, E. De Novo hair follicle morphogenesis and hair tumors in mice expressing a truncated beta-catenin in skin. Cell 1998, 95, 605-614.
147. Harada, N.; Tamai, Y.; Ishikawa, T.; Sauer, B.; Takaku, K.; Oshima, M.; Taketo, M. M. Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. EMBO J. 1999, 18, 5931-5942.
148. Tsujiuchi, T.; Tsutsumi, M.; Sasaki, Y.; Murata, N.; Konishi, Y. Mutations of adenomatous polyposis coli and beta-catenin genes during progression of lung tumors induced by N-nitrosobis(2-hydroxypropyl)amine in rats. Cancer Res. 2000, 60, 6611-6616.
149. Levy, D. B.; Smith, K. J.; Beazer-Barclay, Y.; Hamilton, S. R.; Vogelstein, B.; Kinzler, K. W. Inactivation of both APC alleles in human and mouse tumors. Cancer Res. 1994, 54, 5953-5958.
150. Smith, K. J.; Johnson, K. A.; Bryan, T. M.; Hill, D. E.; Markowitz, S.; Willson, J. K.; Paraskeva, C.; Petersen, G. M.; Hamilton, S. R.; Vogelstein, B.; Kinzler K. W. The APC gene product in normal and tumor cells. Proc. Natl. Acad. Sci. USA 1993, 90, 2846-2850.
151. Capelluto, D. G.; Kutateladze, T. G.; Habas, R.; Finkielstein, C. V.; He, X.; Overduin, M. The DIX domain targets dishevelled to actin stress fibres and vesicular membranes. Nature 2002, 419, 726-729.
152. Kishida, S.; Yamamoto, H.; Ikeda, S.; Kishida, M.; Sakamoto, I.; Koyama, S.; Kikuchi, A. Axin, a negative regulator of the wnt signaling pathway, directly interacts with adenomatous polyposis coli and regulates the stabilization of beta-catenin. J. Biol. Chem. 1998, 273, 10823-10826.
153. Kikuchi, A. Tumor formation by genetic mutations in the components of the Wnt signaling pathway. Cancer Sci. 2003, 94, 225-229.
154. Jin, L. H.; Shao, Q. J.; Luo, W.; Ye, Z. Y.; Li, Q.; Lin, S. C. Detection of point mutations of the Axin1 gene in colorectal cancers. Int. J. Cancer 2003, 107, 696-699.
155. Nakajima, M.; Fukuchi, M.; Miyazaki, T.; Masuda, N.; Kato, H.; Kuwano, H. Reduced expression of Axin correlates with tumour progression of oesophageal
156. Baeza, N.; Masuoka, J.; Kleihues, P.; Ohgaki, H. AXIN1 mutations but not deletions in cerebellar medulloblastomas. Oncogene 2003, 22, 632-636.
157. Satoh, S.; Daigo, Y.; Furukawa, Y.; Kato, T.; Miwa, N.; Nishiwaki, T.; Kawasoe, T.; Ishiguro, H.; Fujita, M.; Tokino, T.; Sasaki, Y.; Imaoka, S.; Murata, M.; Shimano, T.; Yamaoka, Y.; Nakamura, Y. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat. Genet. 2000, 24, 245-250.
158. Dahmen, R. P.; Koch, A.; Denkhaus, D.; Tonn, J. C.; Sorensen, N.; Berthold, F.; Behrens, J.; Birchmeier, W.; Wiestler, O. D.; Pietsch, T. Deletions of AXIN1, a component of the WNT/wingless pathway, in sporadic medulloblastomas. Cancer Res. 2001, 61, 7039-7043.
159. Miao, J.; Kusafuka, T.; Okada, A. Detection of a novel alteration of the Axin gene in various pediatric neoplasms. Oncol. Rep. 2003, 10, 1943-1946.
160. Wolf, D.; Rodova, M.; Miska, E. A.; Calvet, J. P.; Kouzarides, T. Acetylation of beta-catenin by CREB-binding protein (CBP). J. Biol. Chem. 2002, 277, 25562-25567.
161. Giese, K.; Cox, J.; Grosschedl, R. The HMG domain of lymphoid enhancer factor 1 bends DNA and facilitates assembly of functional nucleoprotein structures. Cell 1992, 69, 185-195.
162. Duval, A.; Gayet, J.; Zhou, X. P.; Iacopetta, B.; Thomas, G.; Hamelin, R. Frequent frameshift mutations of the TCF-4 gene in colorectal cancers with microsatellite instability. Cancer Res. 1999, 59, 4213-4215.
163. Kramps, T.; Peter, O.; Brunner, E.; Nellen, D.; Froesch, B.; Chatterjee, S.; Murone, M.; Zullig, S.; Basler, K. Wnt/wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear beta-catenin-TCF complex. Cell 2002, 109, 47-60.
164. Horton, J. Trastuzumab use in breast cancer: clinical issues. Cancer Control 2002, 9, 499-507.
165. Tan, A. R.; Swain, S. M. Ongoing adjuvant trials with trastuzumab in breast cancer. Semin. Oncol. 2003, 30, 54-64.
166. Slamon, D. J.; Clark, G. M.; Wong, S. G.; Levin, W. J.; Ullrich, A.; McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235, 177-182.
167. Rosen, L. S. Angiogenesis inhibition in solid tumors. Cancer J. 2001, 7(Suppl 3), S120-S128.
168. Li, Y. X.; Papkoff, J.; Sarkar, N. H. Antisense downregulation of a mouse mammary tumor virus activated protooncogene in mouse mammary tumor cells reverses the malignant phenotype. Virology 1999, 255, 138-149.
169. He, B.; You, L.; Uematsu, K.; Xu, Z.; Lee, A. Y.; Matsangou, M.; McCormick, F.; Jablons, D. M. A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia 2004, 6, 7-14.
170. You, L.; He, B.; Xu, Z.; Uematsu, K.; Mazieres, J.; Fujii, N.; Mikami, I.; Reguart, N.; McIntosh, J. K.; Kashani-Sabet, M.; McCormick, F.; Jablons, D. M. An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res. 2004, 64, 5385-5389.
171. Vincan, E. Frizzled/WNT signalling: the insidious promoter of tumour growth and progression. Front. Biosci. 2004, 9, 1023-1034.
172. He, X. A Wnt-Wnt situation. Dev. Cell 2003, 4, 791-797.
173. Lee, A. Y.; He, B.; You, L.; Dadfarmay, S.; Xu, Z.; Mazieres, J.; Mikami, I.; McCormick, F.; Jablons, D. M. Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene 2004, 23, 6672-6676.
174. Suzuki, H.; Watkins, D. N.; Jair, K. W.; Schuebel, K. E.; Markowitz, S. D.; Dong Chen, W.; Pretlow, T. P.; Yang, B.; Akiyama, Y.; Van Engeland, M.; Toyota, M.; Tokino, T.; Hinoda, Y.; Imai, K.; Herman, J. G.; Baylin, S. B. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat. Genet. 2004, 36, 417-422.
175. Tsuji, T.; Miyazaki, M.; Sakaguchi, M.; Inoue, Y.; Namba, M. A REIC gene shows down-regulation in human immortalized cells and human tumor-derived cell lines. Biochem. Biophys. Res. Commun. 2000, 268, 20-24.
176. Tsuji, T.; Nozaki, I.; Miyazaki, M.; Sakaguchi, M.; Pu, H.; Hamazaki, Y.; Iijima, O.; Namba, M. Antiproliferative activity of REIC/Dkk-3 and its significant down-regulation in non-small-cell lung carcinomas. Biochem. Biophys. Res. Commun. 2001, 289, 257-263.
177. Hoang, B. H.; Kubo, T.; Healey, J. H.; Yang, R.; Nathan, S. S.; Kolb, E. A.; Mazza, B.; Meyers, P. A.; Gorlick, R. Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res. 2004, 64, 2734-2739.
178. Shou, J.; Ali-Osman, F.; Multani, A. S.; Pathak, S.; Fedi, P.; Srivenugopal, K. S. Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA. Oncogene 2002, 21, 878-889.
179. Kuhnert, F.; Davis, C. R.; Wang, H. T.; Chu, P.; Lee, M.; Yuan, J.; Nusse, R.; Kuo, C. J. Essential requirement for Wnt signaling in proliferation of adult small intestine and colon revealed by adenoviral expression of Dickkopf-1. Proc. Natl. Acad. Sci. USA 2004, 101, 266-271.
180. Shih, I. M.; Yu, J.; He, T. C.; Vogelstein, B.; Kinzler, K. W. The beta-catenin binding domain of adenomatous polyposis coli is sufficient for tumor suppression. Cancer Res. 2000, 60, 1671-1676.
181. Sekiya, T.; Nakamura, T.; Kazuki, Y.; Oshimura, M.; Kohu, K.; Tago, K.; Ohwada, S.; Akiyama, T. Overexpression of Icat induces G(2) arrest and cell death in tumor cell mutants for adenomatous polyposis coli. beta-catenin, or Axin. Cancer Res. 2002, 62, 3322-3326.
182. Dean, N. M.; Bennett, C. F. Antisense oligonucleotide-based therapeutics for cancer. Oncogene 2003, 22, 9087-9096.
183. Advani, R.; Peethambaram, P.; Lum, B. L.; Fisher, G. A.; Hartmann, L.; Long, H. J.; Halsey, J.; Holmlund, J. T.; Dorr, A.; Sikic, B. I. A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. Cancer 2004, 100, 321-326.
184. Jansen, B.; Wacheck, V.; Heere-Ress, E.; Schlagbauer-Wadl, H.; Hoeller, C.; Lucas, T.; Hoermann, M.; Hollenstein, U.; Wolff, K.; Pehamberger, H. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 2000, 356, 1728-1733.
185. Chi, K. N.; Cleave, M. E.; Klasa, R.; Murray, N.; Bryce, C.; Lopes de Menezes, D. E.; D'Aloisio, S.; Tolcher, A. W. A phase 1 dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin. Cancer Res. 2001, 7, 3920-3927.
186. Adjei, A. A.; Dy, G. K.; Erlichman, C.; Reid, J. M.; Sloan, J. A.; Pitot, H. C.; Alberts, S. R.; Goldberg, R. M.; Hanson, L. J.; Atherton, P. J.; Watanabe, T.; Geary, R. S.; Holmlund, J.; Dorr, F. A. A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin. Cancer Res. 2003, 9, 115-123.
187. Iversen, P. L.; Arora, V.; Acker, A. J.; Mason, D. H.; Devi, G. R. Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase 1 safety study in humans. Clin. Cancer Res. 2003, 9, 2510-2519.
188. Rudin, C. M.; Kozloff, M.; Hoffman, P. C.; Edelman, M. J.; Kamauskas, R.; Tomek, R.; Szeto, L.; Vokes, E. E. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J. Clin. Oncol. 2004, 22, 1110-1117.
189. Agrawal, S.; Kandimalla, E. R. Antisense therapeutics: is it as simple as complementary base recognition? Mol. Med. Today 2000, 6, 72-81.
190. Wang, H.; Prasad, G.; Buolamwini, J. K.; Zhang, R. Antisense anticancer oligonucleotide therapeutics. Curr. Cancer Drug Targets 2001, 1, 177-196.
191. Heasman, J.; Crawford, A.; Goldstone, K.; Garner-Hamrick, P.; Gumbiner, B.; McCrea, P.; Kintner, C.; Noro, C. Y.; Wylie, C. Overexpression of cadherins and underexpression of beta-catenin inhibit dorsal mesoderm induction in early Xenopus embryos. Cell 1994, 79, 791-803.
192. Heasman, J.; Kofron, M.; Wylie, C. Beta-catenin signaling activity dissected in the early Xenopus embryo: a novel antisense approach. Dev. Biol. 2000, 222, 124-134.
193. Krufka, A.; Johnson, R. G.; Wylie, C. C.; Heasman, J. Evidence that dorsal-ventral differences in gap junctional communication in the early Xenopus embryo are generated by beta-catenin independent of cell adhesion effects. Dev. Biol. 1998, 200, 92-102.
194. Khokha, M. K.; Chung, C.; Bustamante, E. L.; Gaw, L. W.; Trott, K. A.; Yeh, J.; Lim, N.; Lin, J. C.; Taverner, N.; Amaya, E.; Papalopulu, N.; Smith, J. C.; Zorn, A. M.; Harland, R. M.; Grammer, T. C. Techniques and probes for the study of Xenopus tropicalis development. Dev. Dyn. 2002, 225, 499-510.
195. Matsuda, M.; Keino, H. Roles of beta-catenin in inner ear development in rat embryos. Anat. Embryol. 2000, 202, 39-48.
196. Matsuda, M. Roles of beta-catenin in somitogenesis in rat embryos. In Vitro Cell Dev. Biol. Anim. 2000, 36, 593-599.
197. Monga, S. P.; Monga, H. K.; Tan, X.; Mule, K.; Pediaditakis, P.; Michalopoulos, G. K. Beta-catenin antisense studies in embryonic liver cultures: role in proliferation, apoptosis, and lineage specification. Gastroenterology 2003, 124, 202-216.
198. Haertel-Wiesmann, M.; Liang, Y.; Fantl, W. J.; Williams, L. T. Regulation of cyclooxygenase-2 and periostin by Wnt-3 in mouse mammary epithelial cells. J. Biol. Chem. 2000, 275, 32046-32051.
199. Roh, H.; Green, D. W.; Boswell, C. B.; Pippin, J. A.; Drebin, J. A. Suppression of beta-catenin inhibits the neoplastic growth of APC-mutant colon cancer cells. Cancer Res. 2001, 61, 6563-6568.
200. Green, D. W.; Roh, H.; Pippin, J. A.; Drebin, J. A. Beta-catenin antisense treatment decreases beta-catenin expression and tumor growth rate in colon carcinoma xenografts. J. Surg. Res. 2001, 101, 16-20.
201. Veeramachaneni, N. K.; Kubokura, H.; Lin, L.; Pippin, J. A.; Patterson, G. A.; Drebin, J. A.; Battafarano, R. J. Down-regulation of beta catenin inhibits the growth of esophageal carcinoma cells. J. Thorac. Cardiovasc. Surg. 2004, 127, 92-98.
202. Chung, E. J.; Hwang, S. G.; Nguyen, P.; Lee, S.; Kim, J. S.; Kim, J. W.; Henkart, P. A.; Bottaro, D. P.; Soon, L.; Bonvini, P.; Lee, S. J.; Karp, J. E.; Oh, H. J.; Rubin, J. S.; Trepel, J. B. Regulation of leukemic cell adhesion, proliferation, and survival by beta-catenin. Blood 2002, 100, 982-990.
203. Thompson, B.; Townsley, F.; Rosin-Arbesfeld, R.; Musisi, H.; Bienz, M. A new nuclear component of the Wnt signalling pathway. Nat. Cell Biol. 2002, 4, 367-373.
204. Cong, F.; Schweizer, L.; Chamorro, M.; Varmus, H. Requirement for a nuclear function of beta-catenin in Wnt signaling. Mol. Cell. Biol. 2003, 23, 8462-8470.
205. Kaplan, D. D.; Meigs, T. E.; Kelly, P.; Casey, P. J. Identification of a role for beta-catenin in the establishment of a bipolar mitotic spindle. J. Biol. Chem. 2004, 279, 10829-10832.
206. van de Wetering, M.; Oving, I.; Muncan, V.; Pon Fong, M. T.; Brantjes, H.; van Leenen, D.; Holstege, F. C.; Brummelkamp, T. R.; Agami, R.; Clevers, H. Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector. EMBO Rep. 2003, 4, 609-615.
207. Orlandini, M.; Semboloni, S.; Oliviero, S. Beta-catenin inversely regulates vascular endothelial growth factor-D mRNA stability. J. Biol. Chem. 2003, 278, 44650-44656.
208. Verma, U. N.; Surabhi, R. M.; Schmaltieg, A.; Becerra, C.; Gaynor, R. B. Small interfering RNAs directed against beta-catenin inhibit the in vitro and In vivo growth of colon cancer cells. Clin. Cancer Res. 2003, 9, 1291-1300.
209. Kitagawa, M.; Hatakeyama, S.; Shirane, M.; Matsumoto, M.; Ishida, N.; Hattori, K.; Nakamichi, I.; Kikuchi, A.; Nakayama, K. An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of beta-catenin. EMBO J. 1999, 18, 2401-2410.
210. Hart, M.; Concordet, J. P.; Lassot, I.; Albert, I.; del los Santos, R.; Durand, H.; Perret, C.; Rubinfeld, B.; Margottin, F.; Benarous, R.; Polakis, P. The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr. Biol. 1999, 9, 207-210.
211. Jackson, P. K.; Eldridge, A. G. The SCF ubiquitin ligase: an extended look. Mol. Cell 2002, 9, 923-925.
212. Cong, F.; Zhang, J.; Pao, W.; Zhou, P.; Varmus, H. A protein knockdown strategy to study the function of beta-catenin in tumorigenesis. BMC Mol. Biol. 2003, 4, 10.
213. Su, Y.; Ishikawa, S.; Kojima, M.; Liu, B. Eradication of pathogenic beta-catenin by Skp1/Cullin/F box ubiquitination machinery. Proc. Natl. Acad Sci. USA 2003, 100, 12729-12734.
214. Liu, J.; Stevens, J.; Matsunami, N.; White, R. L. Targeted degradation of beta-catenin by chimeric F-box fusion proteins. Biochem. Biophys. Res. Commun. 2004, 313, 1023-1029.
215. Daniels, D. L.; Eklof Spink, K.; Weis, W. I. Beta-catenin: molecular plasticity and drug design. Trends Biochem. Sci. 2001, 26, 672-678.
216. Wakita, K.; Tetsu, O.; McCormick, F. A mammalian two-hybrid system for adenomatous polyposis coli-mutated colon cancer therapeutics. Cancer Res. 2001, 61, 854-858.
217. Emami, K. H.; Nguyen, C.; Ma, H.; Kim, D. H.; Jeong, K. W.; Eguchi, M.; Moon, R. T.; Teo, J. L.; Oh, S. W.; Kim, H. Y.; Moon, S. H.; Ha, J. R.; Kahn, M. A small molecule inhibitor of beta-catenin/cyclic AMP response element-binding protein transcription. Proc. Natl. Acad. Sci. USA 2004, 101, 12682-12687.
218. Chen, R. H.; McCormick, F. Selective targeting to the hyperactive beta-catenin/T-cell factor pathway in colon cancer cells. Cancer Res. 2001, 61, 4445-4449.
219. Kwong, K. Y.; Zou, Y.; Day, C. P.; Hung, M. C. The suppression of colon cancer cell growth in nude mice by targeting beta-catenin/TCF pathway. Oncogene 2002, 21, 8340-8346.
220. Vecil, G. G.; Lang, F. F. Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses. J. Neurooncol. 2003, 65, 237-246.
221. Alain, T.; Thirukkumaran, C.; Morris, D. G.; Urbanski, S. J.; Janowska-Wieczorek, A.; Lee, P. W.; Kossakowska, A. E. Lymphomas and oncolytic virus therapy. Clin. Lymphoma 2003, 4, 104-111.
222. Lou, E. Oncolytic herpes viruses as a potential mechanism for cancer therapy. Acta Oncol. 2003, 42, 660-671.
223. Zwiebel, J. A. Cancer gene and oncolytic virus therapy. Semin. Oncol. 2001, 28, 336-343.
224. Brunori, M.; Malerba, M.; Kashiwazaki, H.; Iggo, R. Replicating adenoviruses that target tumors with constitutive activation of the wnt signaling pathway. J. Virol. 2001, 75, 2857-2865.
225. Fuerer, C.; Iggo, R. Adenoviruses with Tcf binding sites in multiple early promoters show enhanced selectivity for tumour cells with constitutive activation of the wnt signalling pathway. Gene Ther. 2002, 9, 270-281.
226. Fuerer, C.; Iggo, R. 5-Fluorocytosine increases the toxicity of Wnt-targeting replicating adenoviruses that express cytosine deaminase as a late gene. Gene Ther. 2004, 11, 142-151.
227. Toth, K.; Djeha, H.; Ying, B.; Tollefson, A. E.; Kuppuswamy, M.; Doronin, K.; Krajcsi, P.; Lipinski, K.; Wrighton, C. J.; Wold, W. S. An oncolytic adenovirus vector combining enhanced cell-to-cell spreading, mediated by the ADP cytolytic protein, with selective replication in cancer cells with deregulated wnt signaling. Cancer Res. 2004, 64, 3638-3644.
228. Malerba, M.; Daeffler, L.; Rommelaere, J.; Iggo, R. D. Replicating parvoviruses that target colon cancer cells. J. Virol. 2003, 77, 6683-6691.
229. Sasai, H.; Masaki, M.; Wakitani, K. Suppression of polypogenesis in a new mouse strain with a truncated Apc(Delta474) by a novel COX-2 inhibitor, JTE-522. Carcinogenesis 2000, 21, 953-958.
230. van de Wetering, M.; Sancho, E.; Verweij, C.; de Lau, W.; Oving, L; Hurlstone, A.; van der Horn, K.; Batlle, E.; Coudreuse, D.; Haramis, A. P.; Tjon-Pon-Fong, M.; Moerer, P.; van den Born, M.; Soete, G.; Pals, S.; Eilers, M.; Medema, R.; Clevers, H. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002, 111, 241-250.
231. Wielenga, V. J.; Smits, R.; Korinek, V.; Smit, L.; Kielman, M.; Fodde, R.; Clevers, H.; Pals, S. T. Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am. J. Pathol. 1999, 154, 515-523.
232. Dang, C. V. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol. Cell Biol. 1999, 19, 1-11.
233. Biroccio, A.; Benassi, B.; Florentino, F.; Zupi, G. Glulathione depletion induced by c-Myc downregulation triggers apoptosis on treatment with alkylating agents. Neoplasia 2004, 6, 195-206.
234. Leonetti, C.; Biroccio, A.; Candiloro, A.; Citro, G.; Fornari, C.; Mottolese, M.; Del Bufalo, D.; Zupi, G. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin. Clin. Cancer Res. 1999, 5, 2588-2595.
235. Arango, D.; Corner, G. A.; Wadler, S.; Catalano, P. J.; Augenlicht, L. H. c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and In vivo. Cancer Res. 2001, 61, 4910-4915.
236. Zhang, H. S.; Gavin, M.; Dahiya, A.; Postigo, A. A.; Ma, D.; Luo, R. X.; Harbour, J. W.; Dean, D. C. Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF. Cell 2000, 101, 79-89.
237. Harbour, J. W.; Luo, R. X.; Dei Santi, A.; Postigo, A. A.; Dean, D. C. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 1999, 98, 859-869.
238. Sherr, C. J. D1 in G2. Cell Cycle 2002, 1, 36-38.
239. Whittaker, S. R.; Walton, M. I.; Garrett, M. D.; Workman, P. The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway. Cancer Res. 2004, 64, 262-212.
240. Hidalgo, M.; Rowinsky, E. K. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000, 19, 6680-6686.
241. Petty, W. J.; Dragnev, K. H.; Dmitrovsky, E. Cyclin D1 as a target for chemoprevention. Lung Cancer 2003, 41(Suppl 1), S155-S161.
242. Gupta, R. A.; Tan, J.; Krause, W. F.; Geraci, M. W.; Willson, T. M.; Dey, S. K.; DuBois, R. N. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc. Natl. Acad. Sci. USA 2000, 97, 13275-13280.
243. Araki, Y.; Okamura, S.; Hussain, S. P.; Nagashima, M.; He, P.; Shiseki, M.; Miura, K.; Harris, C. C. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res. 2003, 63, 728-734.
244. Dimberg, J.; Hugander, A.; Sirsjo, A.; Soderkvist, P. Enhanced expression of cyclooxygenase-2 and nuclear beta-catenin are related to mutations in the APC gene in human colorectal cancer. Anticancer Res. 2001, 21, 911-915.
245. Kim, S. J.; Im, D. S.; Kim, S. H.; Ryu, J. H.; Hwang, S. G.; Seong, J. K.; Chun, C. H.; Chun, J. S. Beta-catenin regulates expression of cyclooxygenase-2 in articular chondrocytes. Biochem. Biophys. Res. Commun. 2002, 296, 221-226.
246. Gupta, R. A.; Wang, D.; Katkuri, S.; Wang, H.; Dey, S. K.; DuBois, R. N. Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth. Nat. Med. 2004, 10, 245-247.
247. Wang, D.; Wang, H.; Shi, Q.; Katkuri, S.; Walhi, W.; Desvergne, B.; Das, S. K.; Dey, S. K.; DuBois, R. N. Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell 2004, 6, 285-295.
248. Park, B. H.; Breyer, B.; He, T. C. Peroxisome proliferator-activated receptors: roles in tumorigenesis and chemoprevention in human cancer. Curr. Opin. Oncol. 2001, 13, 78-83.
249. Han, S.; Inoue, H.; Flowers, L. C.; Sidell, N. Control of COX-2 gene expression through peroxisome proliferator-activated receptor gamma in human cervical cancer cells. Clin. Cancer Res. 2003, 9, 4627-4635.
250. Wang, D.; Dubois, R. N. Cyclooxygenase-2: a potential target in breast cancer. Semin. Oncol. 2004, 31, 64-73.
251. Sandler, A. B.; Dubinett, S. M. COX-2 inhibition and lung cancer. Semin. Oncol. 2004, 31, 45-52.
252. Sutton, K. M.; Wright, M.; Fondren, G.; Towle, C. A.; Mankin, H. J. Cyclooxygenase-2 expression in chondrosarcoma. Oncology 2004, 66, 275-280.
253. Dickens, D. S.; Kozielski, R.; Khan, J.; Forus, A.; Cripe, T. P. Cyclooxygenase-2 expression in pediatric sarcomas. Pediatr. Dev. Pathol. 2002, 5, 356-364.
254. Sabichi, A. L.; Lippman, S. M. COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in genitourinary cancer. Semin. Oncol. 2004, 31, 36-44.
255. Fu, S. L.; Wu, Y. L.; Zhang, Y. P.; Qiao, M. M.; Chen, Y. Anticancer effects of COX-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer. World J. Gastroenterol. 2004, 10, 1971-1974.
256. Jiang, J. G.; Tang, J. B.; Chen, C. L.; Liu, B. X.; Fu, X. N.; Zhu, Z. H.; Qu, W.; Cianflone, K.; Waalkes, M. P.; Wang, D. W. Expression of cyclooxygenase-2 in human esophageal squamous cell carcinomas. World J. Gastroenterol. 2004, 10, 2168-2173.
257. Arun, B.; Goss, P. The role of COX-2 inhibition in breast cancer treatment and prevention. Semin. Oncol. 2004, 31, 22-29.
258. Natale, R. B. Irinotecan, cisplatin/carboplatin, and COX-2 inhibition in small-cell lung cancer. Oncology 2003, 17, 22-26.
259. Sweeney, C. J. Why cyclooxygenase-2 inhibition plus chemotherapy? Am. J. Clin. Oncol. 2003, 26, S122-S125.
260. Altorki, N. K.; Keresztes, R. S.; Port, J. L.; Libby, D. M.; Korst, R. J.; Flieder, D. B.; Ferrara, C. A.; Yankelevitz, D. F.; Subbaramaiah, K.; Pasmantier, M. W.; Dannenberg, A. J. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell king cancer. J. Clin. Oncol. 2003, 21, 2645-2650.
261. DuBois, R. N.; Giardiello, F. M.; Smalley, W. E. Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention. Gastroenterol. Clin. North Am. 1996, 25, 773-791.
262. Koehne, C. H.; Dubois, R. N. COX-2 inhibition and colorectal cancer. Semin. Oncol. 2004, 31, 12-21.
263. Oshima, M.; Taketo, M. M. COX selectivity and animal models for colon cancer. Curr. Pharm. Des. 2002, 8, 1021-1034.
264. Williams, J. L.; Nath, N.; Chen, J.; Hundley, T. R.; Gao, J.; Kopelovich, L.; Kashfi, K.; Rigas, B. Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: implications for chemoprevention. Cancer Res. 2003, 63, 7613-7618.
265. Ricchi, P.; Zarrilli, R.; Di Palma, A.; Acquaviva, A. M. Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy. Br. J. Cancer 2003, 88, 803-807.
266. Lew, J. I.; Guo, Y.; Kim, R. K.; Vargish, L.; Michelassi, F.; Arenas, R. B. Reduction of intestinal neoplasia with adenomatous polyposis coli gene replacement and COX-2 inhibition is additive. J. Gastrointest. Surg. 2002, 6, 563-568.
267. Robinson-Rechavi, M.; Carpentier, A. S.; Duffraisse, M.; Laudet, V. How many nuclear hormone receptors are there in the human genome? Trends Genet. 2001, 17, 554-556.
268. Kliewer, S. A.; Umesono, K.; Noonan, D. J.; Heyman, R. A.; Evans, R. M. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 1992, 358, 771-774.
269. Lemberger, T.; Desvergne, B.; Wahli, W. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu. Rev. Cell Dev. Biol. 1996, 12, 335-363.
270. Fajas, L.; Auboeuf, D.; Raspe, E.; Schoonjans, K.; Lefebvre, A. M.; Saladin, R.; Najib, J.; Laville, M.; Fruchart, J. C.; Deeb, S.; Vidal-Puig, A.; Flier, J.; Briggs, M. R.; Staels, B.; Vidal, H.; Auwerx, J. The organization, promoter analysis, and expression of the human PPARgamma gene. J. Biol. Chem. 1997, 272, 18779-18789.
271. Grommes, C.; Landreth, G. E.; Heneka, M. T. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol. 2004, 5, 419-429.
272. Debrock, G.; Vanhentenrijk, V.; Sciot, R.; Debiec-Rychter, M.; Oyen, R.; Van Oosterom, A. A phase II trial with rosiglitazone in liposarcoma patients. Br. J. Cancer 2003, 89, 1409-1412.
273. Demetri, G. D.; Fletcher, C. D.; Mueller, E.; Sarraf, P.; Naujoks, R.; Campbell, N.; Spiegelman, B. M.; Singer, S. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc. Natl. Acad. Sci. USA 1999, 96, 3951-3956.
274. Lu, Z.; Hunter, T. Wnt-independent beta-catenin transactivation in tumor development. Cell Cycle 2004, 3, 571-573.
275. Takahashi, K.; Suzuki, K.; Tsukatani, Y. Induction of tyrosine phosphorylation and association of beta-catenin with EGF receptor upon tryptic digestion of quiescent cells at confluence. Oncogene 1997, 15, 71-78.
276. Lu, Z.; Ghosh, S.; Wang, Z.; Hunter, T. Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell 2003, 4, 499-515.
277. Vlahovic, G.; Crawford, J. Activation of tyrosine kinases in cancer. Oncologist 2003, 8, 531-538.
278. Ross, D. M.; Hughes, T. P. Cancer treatment with kinase inhibitors: what have we learnt from imatinib? Br. J. Cancer 2004, 90, 12-19.
279. Erlotinib: CP 358774, NSC 718781, OS1 774, R 1415. Drugs R D 2003, 4, 243-248.
280. Zhou, L.; An, N.; Haydon, R.; Zhou, Q.; Cheng, H.; Peng, Y.; Jiang, W.; Luu, H.; Vanichakarn, P.; Szatkowski, J.; Park, J.; Breyer, B.; He, T.-C. Tyrosine kinase inhibitor ST1-571/Gleevec down-regulates the beta-catenin signaling activity. Cancer Lett. 2003, 193, 161-170.
281. Torrance, C. J.; Jackson, P. E.; Montgomery, E.; Kinzler, K. W.; Vogelstein, B.; Wissner, A.; Nunes, M.; Frost, P.; Discafani, C. M. Combinatorial chemoprevention of intestinal neoplasia. Nat. Med. 2000, 6, 1024-1028.
282. Garattini, E.; Gianni, M.; Terao, M. Retinoid related molecules an emerging class of apoptotic agents with promising therapeutic potential in oncology: pharmacological activity and mechanisms of action. Curr. Pharm. Des. 2004, 10, 433-448.
283. Freemantle, S. J.; Spinella, M. J.; Dmitrovsky, E. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene 2003, 22, 7305-7315.
284. Suzui, M.; Masuda, M.; Lim, J. T.; Albanese, C.; Pestell, R. G.; Weinstein, I. B. Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21(CIPI) and inhibition of expression of cyclin D1. Cancer Res. 2002, 62, 3997-4006.
285. Shah, S.; Hecht, A.; Pestell, R.; Byers, S. W. Trans-repression of beta-catenin activity by nuclear receptors. J. Biol. Chem. 2003, 275, 48137-48145.
286. Shah, S.; Pishvaian, M. J.; Easwaran, V.; Brown, P. H.; Byers, S. W. The role of cadherin, beta-catenin, and AP-1 in retinoid-regulated carcinoma cell differentiation and proliferation. J. Biol. Chem. 2002, 277, 25313-25322.
287. Jimi, S.; Shono, T.; Tanaka, M.; Kono, A.; Yamada, Y.; Shudo, K.; Kuwano, M. Effect of retinoic acid on morphological changes of human pancreatic cancer cells on collagen gels: a possible association with the metastatic potentials. Oncol. Res. 1998, 10, 7-14.
288. Druker, B. J. Perspectives on the development of a molecularly targeted agent. Cancer Cell 2002, 1, 31-36.
289. Korinek, V.; Barker, N.; Morin, P. J.; van Wichen, D.; de Weger, R.; Kinzler, K. W.; Vogelstein, B.; Clevers, H. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma [see comments]. Science 1997, 275, 1784-1787.
290. Zhou, L.; An, N.; Jiang, W.; Haydon, R.; Cheng, H.; Zhou, Q.; Breyer, B.; Feng, T.; He, T. C. Fluorescence-based functional assay for Wnt/beta-catenin signaling activity. Biotechniques 2002, 33, 1126-1128, 1130, 1132 passim.
291. Lepourcelet, M.; Chen, Y. N.; France, D. S.; Wang, H.; Crews, P.; Petersen, F.; Bruseo, C.; Wood, A. W.; Shivdasani, R. A. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell 2004, 5, 91-102.
292. Easwaran, V.; Lee, S. H.; Inge, L.; Guo, L.; Goldbeck, C.; Garrett, E.; Wiesmann, M.; Garcia, P. D.; Fuller, J. H.; Chan, V.; Randazzo, F.; Gundel, R.; Warren, R. S.; Escobedo, J.; Aukerman, S. L.; Taylor, R. N.; Fantl, W. J. Beta-Catenin regulates vascular endothelial growth factor expression in colon cancer. Cancer Res. 2003, 63, 3145-3153.
293. Heinen, C. D.; Goss, K. H.; Cornelius, J. R.; Babcock, G. F.; Knudsen, E. S.; Kowalik, T.; Groden, J. The APC tumor suppressor controls entry into S-phase through its ability to regulate the cyclin D/RB pathway. Gastroenterology 2002, 123, 751-763.